
Havrix Monodose
Havrix is indicated for active immunisation against hepatitis A virus infection
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
PA: PA 1077/026/002. MA holder: GlaxoSmithKline (Ireland) Ltd, 12 Riverwalk, Citywest, Dublin 24. For further information please contact: GlaxoSmithKline (Ireland) Ltd, 12 Riverwalk, Citywest, Dublin 24. Telephone: 01-4955000.
POM S1A.
Havrix is a registered trademark of the GlaxoSmithKline Group of Companies.